The Achilles heel of TNBCs Ferroptosis heterogeneity

Resistance to ferroptosis, a form of programmed cell death, is associated with the development of some refractory cancers. In this issue, Yang et al. systematically illustrate the ferroptosis heterogeneity in triple-negative breast cancers (TNBCs) and reveal an innovative immunotherapy combination strategy for the luminal androgen receptor (LAR) subtype of TNBC.

Automated summary

Resistance to programmed cell death called ferroptosis is linked to the development of certain difficult-to-treat cancers. Yang et al. provide a comprehensive understanding of the heterogeneity of ferroptosis in triple-negative breast cancers (TNBCs) and propose an innovative immunotherapy combination strategy for the luminal androgen receptor (LAR) subtype of TNBC.